275 related articles for article (PubMed ID: 32073826)
1. Delivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage.
Bouzinab K; Summers HS; Stevens MFG; Moody CJ; Thomas NR; Gershkovich P; Weston N; Ashford MB; Bradshaw TD; Turyanska L
ACS Appl Mater Interfaces; 2020 Mar; 12(11):12609-12617. PubMed ID: 32073826
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue.
Heravi Shargh V; Luckett J; Bouzinab K; Paisey S; Turyanska L; Singleton WGB; Lowis S; Gershkovich P; Bradshaw TD; Stevens MFG; Bienemann A; Coyle B
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35266-35280. PubMed ID: 34310112
[TBL] [Abstract][Full Text] [Related]
3. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
Zhang J; Hummersone M; Matthews CS; Stevens MF; Bradshaw TD
Oncology; 2015; 88(1):28-48. PubMed ID: 25277441
[TBL] [Abstract][Full Text] [Related]
4. Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma.
Renziehausen A; Tsiailanis AD; Perryman R; Stylos EK; Chatzigiannis C; O'Neill K; Crook T; Tzakos AG; Syed N
Mol Cancer Ther; 2019 Sep; 18(9):1497-1505. PubMed ID: 31213505
[TBL] [Abstract][Full Text] [Related]
5. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.
Du K; Xia Q; Heng H; Feng F
ACS Appl Mater Interfaces; 2020 Aug; 12(31):34599-34609. PubMed ID: 32648735
[TBL] [Abstract][Full Text] [Related]
7. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
He Y; Kaina B
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide: mechanisms of action, repair and resistance.
Zhang J; Stevens MF; Bradshaw TD
Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
[TBL] [Abstract][Full Text] [Related]
9. Effect of O6-Substituted Guanine Analogs on O6-methylguanine DNA-methyltransferase Expression and Glioblastoma Cells Viability.
St-Coeur PD; Cormier M; LeBlanc VC; Morin PJ; Touaibia M
Med Chem; 2016; 13(1):28-39. PubMed ID: 27396904
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme.
Li X; Shao F; Sun J; Du K; Sun Y; Feng F
ACS Appl Mater Interfaces; 2019 Nov; 11(45):41935-41945. PubMed ID: 31644262
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
12. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Efficacy of Temozolomide Loaded by a Tetrahedral Framework DNA Nanoparticle in the Therapy for Glioblastoma.
Fu W; You C; Ma L; Li H; Ju Y; Guo X; Shi S; Zhang T; Zhou R; Lin Y
ACS Appl Mater Interfaces; 2019 Oct; 11(43):39525-39533. PubMed ID: 31601097
[TBL] [Abstract][Full Text] [Related]
14. C8-Substituted Imidazotetrazine Analogs Overcome Temozolomide Resistance by Inducing DNA Adducts and DNA Damage.
Yang Z; Wei D; Dai X; Stevens MFG; Bradshaw TD; Luo Y; Zhang J
Front Oncol; 2019; 9():485. PubMed ID: 31263673
[TBL] [Abstract][Full Text] [Related]
15. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
16. Encapsulation of copper phenanthroline within horse spleen apoferritin: characterisation, cytotoxic activity and ability to retain temozolomide.
Cassioli ML; Fay M; Turyanska L; Bradshaw TD; Thomas NR; Pordea A
RSC Adv; 2024 Apr; 14(20):14008-14016. PubMed ID: 38686295
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
[TBL] [Abstract][Full Text] [Related]
18. Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells.
Zampieri LX; Sboarina M; Cacace A; Grasso D; Thabault L; Hamelin L; Vazeille T; Dumon E; Rossignol R; Frédérick R; Sonveaux E; Lefranc F; Sonveaux P
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769368
[TBL] [Abstract][Full Text] [Related]
19. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
Gupta SK; Kizilbash SH; Carlson BL; Mladek AC; Boakye-Agyeman F; Bakken KK; Pokorny JL; Schroeder MA; Decker PA; Cen L; Eckel-Passow JE; Sarkar G; Ballman KV; Reid JM; Jenkins RB; Verhaak RG; Sulman EP; Kitange GJ; Sarkaria JN
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26615020
[TBL] [Abstract][Full Text] [Related]
20. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
